In the last 10 years the incidence of type 2 diabetes (T2DM) 
Introduction
The real prevalence of pediatric type 2 diabetes (T2DM) is unknown in many countries. However, it seems that the incidence of T2DM in children is increasing, so the American Diabetes Association (ADA) recommends screening of at-risk asymptomatic children [1] . T2DM in children and adolescents is more common in some minority populations: black African descents, Central and South Americans, native North Americans, South Asians (Indian Peninsula), Asians and Native Pacific Islander [2] . In the United States, T2DM represented about 3% of pediatric diabetes in 1990. Approximately ten years later, in 2003, it represented 20% of pediatric diabetes [3, 4] .
Obesity, positive family history for diabetes, belonging to specific racial and ethnic groups, female gender and conditions associated with insulin resistance such as polycystic ovary syndrome (PCOS), are the risk factors increasing the risk for childhood onset T2DM. At the onset of puberty (generally around the mean age of 13.5 years [4, 5] when insulin resistance is increased by approximately 30% due to the increased secretion of growth hormone and insulin-like growth factor-1), children at risk can develop T2DM [6, 7] .
The risk factors for cardiovascular disease may already exist at the time of diagnosis and recent studies have shown that the rates of hypertension, dyslipidemia and microalbuminuria in adolescents with T2DM are significantly higher than in adolescents with T1DM [8, 9] .
In January 2013, the American Academy of Pediatrics (AAP) published the guideline for the ADA recommends beginning screening at the age of 10 years or at onset of puberty (if puberty occurs at a younger age) and repeating the screening every 3 years [1] .
Recommendations for management of T2DM in children and adolescents
Weight loss, increase in exercise capacity, normalization of glycemia and control of comorbidities (hypertension, dyslipidemia, hepatic steatosis and nephropathy) are important components in the management of pediatric T2DM [2].
Lifestyle changes in diet and exercise are recommended to increase insulin sensitivity in addition to pharmacologic therapy [2] . Currently, metformin is the only Food and Drug Administration (FDA) approved oral treatment for T2DM in children and youth while insulin is approved in many countries [11] . Sulphonylureas are approved for pediatric use in some countries [1] .
Metformin is the most used oral antihypergylcemic agent in T2DM, inhibiting hepatic glucose production, increasing peripheral and liver sensitivity to insulin and decreasing intestinal glucose uptake [12] . An excellent review of the molecular mechanisms of metformin action on hepatic gluconeogenesis was recently published [13] .
Metformin has also anti-lipolytic effects, lowering circulating free fatty acid levels. In vivo and in vitro, metformin activates the adenosine monophosphate-activated protein kinase pathway (AMPK), increasing fatty acid oxidation in hepatocytes, skeletal muscle cells and mouse ovarian tissue and decreasing glucose production [14] . In girls with polycystic ovary syndrome (PCOS), metformin may normalise ovulatory abnormalities increasing pregnancy risk. 
Efficacy and safety of treatment with metformin in pediatric subjects
A study performed by Gottschalk M et al. compared the efficacy and safety of the treatment with glimepiride versus metformin in children and adolescents with T2DM inadequately controlled with lifestyle intervention alone or with oral monotherapy [15] . In this study, 285 children aged 8-17 years old with HbA1c between 7.1% and 12% were randomized to receive glimepiride 1mg-8mg once daily or metformin 500mg-1000 mg twice daily for 24 weeks. All the children were included in two age-related groups (≤12 years or >12 years) and randomly assigned in a one-forone ratio to receive glimepiride or metformin for 24-weeks. The study showed a significant reduction from baseline in HbA1c for both the glimepiride (-0.54%, p=0.001) and metformin (-0.71%, p=0.0002) groups. So, glimepiride reduced HbA1c similarly to metformin but with greater weight gain (1.97 kg in the glimepiride group and 0.55 kg in the metformin group, p=0.005) while the percent of children who had one or more adverse events was similar between the two groups: (59.2% glimepiride and 57.7% metformin) [15] .
In a randomized controlled trial published in 2002 in Diabetes Care, Jones KL et al. reported that metformin significantly lowered HbA1c after 16 weeks compared with placebo (7.5% versus 8.6%) for the maximum tolerated dose of 2000 mg/dl, in adolescents with new-onset T2DM [16] .
Flint A et al. reported that the majority of T2DM children and adolescents maintain good glycemic control (HbA1C<7%) with metformin and lifesyle intervention for the first 2-3 years of disease [17] .
In another study [18] , Gómez-Díaz RA et al. studied the effect of metformin on resistin and other markers of insulin resistance and inflammation in children with glucose intolerance aged 4 to 17 years. A total of 52 patients (11.9±2.6 years old) were randomized to receive 850 mg metformin or placebo twice daily for 12 weeks, period during which they received an iso-caloric diet and followed an exercise program. 28 patients (12males/16 females) received metformin and 24 placebo (11males/13 females). The study showed that metformin was associated with a significant decrease in Homeostasis Model of AssessmentInsulin Resistance (HOMA-IR) index (p=0.032) and HbA1c levels (p=0.001). The percent of patients with weight loss was greater in the metformin group (-5.86% vs. 2.57%, p<0.05) and there was a significant reduction of plasma resistin levels in children with glucose intolerance, but no changes were reported in the concentration of other markers of inflammation [18] .
The Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) study included 699 subjects aged 10 to 17 years with T2DM of less than 2 years duration [19] . Subjects had HbA1c <8%, BMI ≥85th percentile, positive C-peptide and no evidence of pancreatic autoimmunity. Patients were randomly assigned to one of three arms: metformin alone, metformin plus rosiglitazone and metformin plus intensive lifestyle intervention, titrating metformin to 1000 mg twice daily and rosiglitazone to 4 mg twice daily [18] . After six months, the percent of subjects obtaining the weight loss target was significantly higher in the metformin plus lifestyle intervention group (31.2%) than in the metformin plus rosiglitazone group (16.7%, p<0.001) but not significantly different from metformin alone (24.3%). In only half of the subjects, the treatment with metformin alone was effective in maintaining durable glycemic control while the addition of rosiglitazone to metformin, was superior to metformin alone and also superior to metformin and intensive lifestyle intervention. The results of TODAY study show that a majority of children with T2DM may require combination treatment (but metformin alone is approved for use in children) or insulin therapy within a few years after diagnosis [19] .
Conclusions
Metformin is the most widely used drug for the treatment of T2DM in adults. In the same time, the use of metformin increases in pediatric age because of the worldwide surge in pediatric obesity and diabetes.
The current AAP guideline recommends to initiate lifestyle changes in diet and physical activity and to administrate metformin as the first-line therapy in youth with newly T2DM with mild hyperglycemia and without ketonuria or severe hyperglycemia. At present, the results of several studies show that the treatment with metformin is safe and not associated with severe complications in children and adolescents. In the same time, the efficacy of metformin for the treatment of polycystic ovary syndrome (PCOS) and T2DM in children is well demonstrated. However, only modest improvement in BMI in adolescents with obesity and normal glucose tolerance was observed so that there is no sufficient evidence to use metformin for the treatment of obesity or for the prevention of T2DM.
